MEDIA INQUIRIES
Bernadette Cupit (908) 334-4554
bcupit@omeza.com
-
Omeza announces closing of $8.5 Million Series A financing co-led by Astanor and BluKap Ventures, with participation from Catalyst Investments
Round positions Omeza to accelerate clinical development and scale nationwide commercialization of its FDA-cleared regenerative wound care platform Sarasota, FL – April 16th, 2026 – Omeza Holdings, Inc. (“Omeza”), a commercial-stage advanced …
-
Omeza will be attending the upcoming Symposium on Advanced Wound Care (SAWC) Fall 2025, September 4-6, 2025
Contact cflowers@omeza.com if interested in learning more about our company. Omeza will be in attendance alongside our national distributor, Advanced Solution. About OMEZA Omeza® is a commercial-stage regenerative skin and wound-care company that develops …
-
Advanced Solution and Omeza Holdings Inc. Announce Exclusive National Commercialization Partnership for Revolutionary Wound Care Product, Omeza’s OCMTM
– Exclusive distribution agreement aims to expand access to cutting-edge wound care solutions nationwide. – Carlisle, PA – May 19, 2025 – Advanced Solution, a national leader in regenerative medicine distribution, is proud to …
-
Case Studies of Patients with Diabetic Foot Ulcers Showed 90 to 100 Percent Wound Closure at 12 weeks Following Weekly Treatment with Novel OMEZA® OCM™
–Three case studies reinforce clinical trial data demonstrating dramatic healing rates among patients with diabetic foot ulcers treated with OCM™ – CLEVELAND – June 11, 2024 – Omeza®, a regenerative skincare company …
